Comprehensive Epilepsy Center & Epilepsy Research Unit in Hawaii Investigates BHV-7000 selective activator of Kv7.2/7.3 potassium channels for Epilepsy among Stanford, UCLA, UCSD and U Penn, *Honolulu, Hawaii September 2024*

According to Biohaven website, Focal onset epilepsy, also called partial epilepsy, is the most common form of epilepsy. Despite current therapies, a high unmet need exists for further seizure reduction with reduced side effects, for people who are still experiencing seizures while taking currently available anti-seizure medications. About 33% of adults fall into this group. Biohaven is working with top US Epilepsy Centers including Stanford, UCLA, U Penn and Hawaii Comprehensive Epilepsy Center, & Hawaii Epilepsy Research Unit to research an investigational medication that may be able to help provide better seizure freedom with fewer side effects.

BHV-7000 is highly selective for Kv7.2/7.3 channels, avoiding activation of the GABAA receptor in vitro, thereby reducing the potential for off-target effects. BHV-7000 is structurally distinct from other Kv7 activators, demonstrates potent anti-seizure effects and is well-tolerated in preclinical seizure models, and has shown potential to be a best-in-class Kv7 activator to regulate the hyperexcitable state in epilepsy - Potent in the maximal electroshock seizure test without impact on neurobehavior or motor behavior, Demonstrated minimal GABAA receptor activation, potentially providing better tolerability.

NIH Info: Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy. Who can participate?

18 to 75 years with a Diagnosis of Focal Onset Epilepsy uncontrolled on current medications.

"Our neurologists, epileptologists & researchers at Hawaii's Comprehensive Epilepsy Center & Epilepsy Research Unit are honored to contribute to this important study and making available this option to our local island populations who no longer has to travel to Mainland for advanced epilepsy treatments" Kore Kai Liow, MD, Neurologist & Principal Investigator, Hawaii Comprehensive Epilepsy Center and Video-EEG Epilepsy Monitoring Unit (EMU), Hawaii Epilepsy Research Unit, Dedicated research hotline (808) 564-6141 or info@HawaiiNeuroscience.com